Revance Therapeutics (RVNC) Misses Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Revance Reports Second Quarter 2021 Financial Results, Provides Corporate Update
August 5, 2021 4:05 PM EDT- Q2 revenue for the RHA® Collection of dermal fillers of $17.0 million
- Aesthetic accounts increased to over 2,000 from over 1,500 in the prior quarter
- Fintech payment processing volume run-rate increased to over $500 million in Q2
- U.S. Food and Drug Administration (FDA) pre-approval inspection initiated in June, with approval of DaxibotulinumtoxinA for Injection for the treatment of glabellar lines anticipated in second half 2021
- Conference call and webcast today at 4:30 p.m. ET
NASHVILLE, Tenn.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a... More
